Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis: a Multicenter Randomized Controlled Non-inferiority Study
Nantes University Hospital
422 participants
Jun 11, 2026
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.
Eligibility
Inclusion Criteria10
- Definite infective endocarditis according to the 2023 Duke ISCVID criteria or confirmed by the endocarditis team if the endocarditis was classified as possible
- Prosthetic valve endocarditis
- At least one positive blood culture due to Staphylococcus sp (S. aureus or CoNS)
- After the first positive blood culture, at least one negative blood culture (after a minimum of 72 hours of incubation)
- Infective endocarditis due to Staphylococcus sp (S. aureus or coagulase negative staphylococci) susceptible to rifampin
- Antistaphylococcal treatment for endocarditis introduced less than 14 days ago. We do not consider all antibiotic received before the first positive blood culture
- Age ≥ 18-year-old
- Informed, written consent obtained from patient or from patient's near in kin
- Patient insured under a health insurance scheme
- Patient with adequate contraceptive measure
Exclusion Criteria20
- Presence of cardiovascular implanted electronic device with suspected device-related IE without removal of the device
- Expected duration of follow-up <6 months at the time of randomization
- Patient moribund (expected to die in next 48 hours with or without treatment)
- Patients already receiving more than 72 hours of rifampin for the endocarditis treatment prior to randomization
- Positive blood cultures less than 72 hours before randomization
- Medical history of infective endocarditis in the last 3 months
- True allergy to rifampin or a severe intolerance to rifampin
- Contraindication to rifampin
- Patients requiring treatment contraindicated or not recommended with rifampin or incompatible with the inducer effect of rifampicin according to the marketing authorisation.
- ALAT increase greater than 3 times the upper laboratory range
- Extreme weight (< 45 kg or > 150 kg)
- Patients with confirmed prosthetic vascular graft infection or orthopedic-device-related infection
- Patients treated with rifampin for infections other than endocarditis, such as tuberculosis
- Pregnancy or breastfeeding woman
- Inclusion in another drug clinical trial
- Patients who have already been included in the study for a previous episode of endocarditis
- Patients under court protection, guardianship or trusteeship
- Patients who do not speak or understand French language
- Patient unable to collect information in a daily journal
- Patient unable to understand a follow-up by phone contact
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rifampin-free regimen. The choice of other antibiotics is at the discretion of the physicians in charge but should be in accordance with the 2023 ESC guidelines and 2025 French guidelines (AEPEI/SPILF).
Rifampin containing regimen (900 mg/day). Antibiotic treatment of endocarditis in accordance with the 2023 ESC guidelines and 2025 French guidelines.
Locations(31)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07345325